You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased.
The firm has characterized the new product as a way to seize an opportunity, rather than a shift from its ID-AST focus.
he company said that it added 13 net new commercially contracted instruments globally, including 21 new contracts in the US.
The revenues are in line with analysts' average estimate, but due to the COVID-19 pandemic, it suspended its 2020 guidance.
Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.
Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.
As part of the new sales process the firm launched a return-on-investment tool that adapts data from existing customers to predict potential outcomes.
The firm placed 137 commercially contracted instruments in the quarter and 304 in the full year 2019.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.